AstraZeneca has lifted the veil on the large-scale THALES trial of its antiplatelet drug Brilinta in stroke, the company’s last big hope for recouping its substantial investmen
The FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce the chances of patients having recurring stro
Stroke is a major cause of disability and death worldwide and the third most common cause of death in developed countries. Nearly six million people die from stroke every year and another five million are left permanently disabled.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.